Laurion Capital Management LP bought a new stake in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $6,090,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Carnegie Capital Asset Management LLC lifted its stake in shares of Crispr Therapeutics by 49.4% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 37,610 shares of the company’s stock worth $2,291,000 after buying an additional 12,440 shares in the last quarter. Oxford Asset Management LLP raised its stake in Crispr Therapeutics by 95.6% during the 4th quarter. Oxford Asset Management LLP now owns 27,306 shares of the company’s stock valued at $1,663,000 after buying an additional 13,346 shares during the last quarter. Jefferies Group LLC bought a new position in shares of Crispr Therapeutics during the 4th quarter valued at $1,745,000. Virtus ETF Advisers LLC purchased a new position in shares of Crispr Therapeutics in the 4th quarter worth $384,000. Finally, Stifel Financial Corp boosted its stake in shares of Crispr Therapeutics by 18.0% in the 4th quarter. Stifel Financial Corp now owns 11,562 shares of the company’s stock worth $705,000 after buying an additional 1,767 shares during the last quarter. 52.04% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on CRSP shares. Piper Jaffray Companies restated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 16th. Oppenheimer upped their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Zacks Investment Research upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $84.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Crispr Therapeutics presently has an average rating of “Buy” and a consensus target price of $73.04.

Crispr Therapeutics stock traded down $1.32 during mid-day trading on Monday, hitting $36.32. The stock had a trading volume of 37,640 shares, compared to its average volume of 1,083,612. Crispr Therapeutics AG has a one year low of $33.55 and a one year high of $74.00. The firm has a market capitalization of $2.32 billion, a P/E ratio of 37.47 and a beta of 2.74. The firm’s 50 day moving average is $52.49 and its 200 day moving average is $53.35.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $1.19. The business had revenue of $77.00 million for the quarter, compared to the consensus estimate of $39.08 million. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The business’s revenue was up 76900.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.92) earnings per share. On average, research analysts predict that Crispr Therapeutics AG will post -4.54 earnings per share for the current year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: Earnings Reports

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link